Answers are grounded in this paper and cite their sources.
Low myocardial PKG activity contributes to increased cardiomyocyte stiffness and oxidative stress in HFPEF, suggesting it as a potential therapeutic target.
Low myocardial PKG activity in HFPEF was associated with raised cardiomyocyte F(passive) and was related to increased myocardial nitrosative/oxidative stress. The latter was probably induced by the high prevalence in HFPEF of metabolic comorbidities. Correction of myocardial PKG activity could be a target for specific HFPEF treatment.
No takes yet. Share an insight, caveat, or question.
Heerebeek et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: